The combination of pembrolizumab and lenvatinib has durable antitumor activity and promising survival outcomes in treatment-naïve patients with advanced non-clear-cell renal cell carcinoma, say the KEYNOTE-B61 investigators.

The KEYNOTE-671 trial points to a significant improvement in event-free survival for patients with early-stage, non-small-cell lung cancer with use of pembrolizumab before and after surgery.

medwireNews : The US FDA has approved elacestrant  for advanced breast cancer and also allowed the adjuvant use of pembrolizumab  for resectable non-small-cell lung cancer (NSCLC).

The latest findings from the EV-103 study add support for the first-line use of enfortumab vedotin plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

A novel segmental facial brainstem sensory syndrome has been identified in three patients treated with pembrolizumab, thought to be caused by autoantibody binding to the surface of neurons.

Adding pembrolizumab to etoposide plus platinum continues to improve the outcomes of treatment-naïve people with extensive-stage small-cell lung cancer in the long term, suggest follow-up data from KEYNOTE-604.

Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.

Adding pembrolizumab to chemotherapy significantly improves the overall survival of people with advanced triple-negative breast cancer and a tumoral PD-L1 combined positive score of at least 10, demonstrate phase 3 trial data.

Ramucirumab plus pembrolizumab significantly improves overall survival versus standard of care in people with advanced non-small-cell lung cancer previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.

Combination treatment with sacituzumab govitecan plus pembrolizumab has encouraging efficacy in metastatic urothelial cancer patients who have progressed on platinum-based therapy, report the TROPHY-U-01 researchers. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

The PEARLS/KEYNOTE-091 trial has demonstrated a significant improvement in disease-free survival with the use of adjuvant pembrolizumab versus placebo for patients with resectable non-small-cell lung cancer regardless of PD-L1 expression.

Extended follow-up data from the KEYNOTE-564 study show that adjuvant pembrolizumab continues to offer a disease-free survival benefit over placebo in people with renal cell carcinoma at an intermediate-high or high postsurgery recurrence risk.

Petros Grivas explains why sacituzumab govitecan plus pembrolizumab – investigated in cohort 3 of the TROPHY-U-01 study comprising metastatic urothelial cancer patients with progression after platinum-based treatment – is not ready for prime time, but merits further investigation in this setting. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended expanding the indication for pembrolizumab  to include patients with advanced triple negative breast cancer (TNBC) and PD-L1 expression of at least 10%.

This decision follows the positive results of the phase 3 CLEAR trial , which showed a significant progression-free and overall survival benefit with use of lenvatinib plus pembrolizumab relative to sunitinib.

medwireNews : The US FDA has approved the combination of lenvatinib and pembrolizumab for treatment-naïve adult patients with advanced renal cell carcinoma (RCC).

This approval is based on the findings of the KEYNOTE-522 trial  demonstrating significantly better pathologic complete response with pembrolizumab–chemotherapy over chemotherapy alone (63 vs 56%), as well as a significant 37% reduction in the risk for a progression event with the addition of pembrolizumab.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improves event-free survival rates versus neoadjuvant chemotherapy alone in people with a new diagnosis of early-stage triple-negative breast cancer, KEYNOTE-522 study data show.

Here, we describe the case of an exon-19-deleted patient who experienced a complete response to the anti-PD-1 agent pembrolizumab upon the development of T790M-negative acquired resistance to afatinib.